Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Pricing: National Academies Weighs In With Some Familiar Proposals

Executive Summary

Government price negotiations, financial transparency in the drug supply chain and changes to orphan drug incentives would go a long way toward making drugs more affordable, a National Academies committee says in a new report; dissent authored by two pharma industry veterans warns of 'unintended consequences' if recommendations are implemented.

You may also be interested in...



Rebate Proposals Targeting Single-Use Vials May Be Barking Up The Wrong Tree

Policymakers should instead focus on increasing efficiencies in drug development, distribution and reimbursement, National Academies report says, while also seeking broad policies like HHS direct negotiation for drug prices in Medicare.

DTC Price Disclosure Should Include Cost Sharing Context, Patient Groups Tell CMS

Some patient groups, payers support CMS proposal to require disclosure of list prices in TV ads but want to expand the requirement to other media and beef up enforcement. Others are skeptical the proposal would lower prices.

The Economics Of Drug Shortages: US FDA Seeks Broad Input

FDA is planning series of stakeholder meetings to identify new approaches to drug shortages, with particular interest in defining “essential” drugs. Agency is also looking outside for expertise, with Boston University’s Rena Conti tapped as advisor.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel